UNSPSC 51184014: Metahexamide

This classification denotes an anti-diabetic agent with the molecular formula C14H21N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) T3U6F5D722, chemically known as 1,3,5-triazine-2,4-diamine, 6-chloro-n,n,n,n-tetraethyl- but more generally known as metahexamide, which bears US NIH Compound Identifier 11259. European Medicines Agency schedules Metahexamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08803MIG.

UNSPSC 51184014 Metahexamide is a Commodity code representing generic pharmaceutical products being procured by state and local government health systems and facilities through cooperative purchasing vehicles. State and local governments buy metahexamide and similar diabetes medications as part of formulary stocking for hospitals, clinics, correctional health systems, and other public health facilities; the code captures individual active pharmaceutical ingredients sourced by volume through authorized pharmaceutical wholesalers. The issuing bodies soliciting under this code are primarily state health departments and multistate cooperative purchasing alliances that bundle pharmaceutical procurement across member agencies—state facilities, county systems, municipalities, and regional health authorities all draw from centrally negotiated contracts. Repeat buyers include state Medicaid programs and dedicated pharmacy procurement offices within departments of corrections, mental health, and public health.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and meet cGMP certification, DSCSA compliance, and FDA requirements. The contract term runs two years for new responders with optional MMCAP extensions, or through June 30, 2028 for incumbent vendors. Evaluation is weighted primarily on price competitiveness (75 percent), with the remainder divided among fixed pricing (10 percent), EDI capability (5 percent), administrative fee acceptance (5 percent), and format compliance (5 percent). Vendors must carry workers' compensation, $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability coverage, and accept a 3 percent administrative fee on all contract purchases.